Chai Discovery signs AI antibody design licensing deal with Pfizer

On June 5, 2026, Chai Discovery announced a license agreement allowing Pfizer scientists to use its AI platform, including the new Chai‑3 model, in Pfizer’s drug discovery workflows. The deal gives Pfizer early access to Chai‑3 and a custom model trained on Pfizer’s proprietary data to speed antibody and biologics design.